Analysts who follow OncoCyte Corp (OCX) on average expect it to add 78.57% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns OCX an Analyst Ranking of 28, which means it ranks higher than 28 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With OncoCyte Corp Stock Today?
OncoCyte Corp (OCX) stock has risen 10.27% while the S&P 500 has fallen -1.19% as of 3:12 PM on Thursday, Sep 17. OCX has risen $0.15 from the previous closing price of $1.46 on volume of 396,220 shares. Over the past year the S&P 500 is up 11.26% while OCX has fallen -27.48%. OCX lost -$0.51 per share the over the last 12 months.
Click Here to get the full report on OncoCyte Corp (OCX) Stock.
